A wave of megadeal activity in Europe isn't providing the trading opportunities many hedge funds had hoped for.
US drug firm Pfizer 's $120 billion attempt to buy UK rival AstraZeneca and General Electric's GE proposed $17 billion purchase of French group Alstom's power business are seen by many investors as kicking off a long-awaited boom in M&A in Europe.